Keywords
Health expenditures
Cost-benefit analysis
How to Cite
Copyright © | All rights reserved.
The journal holds the exclusive copyright for the publication of this article under the terms of Brazilian law 9610/98.
Partial reproduction
The use of parts of the texts, figures and questionnaire of the article is free, being mandatory the citation of the authors and journal.
Total reproduction
It is expressly prohibited and must be authorized by the journal.
Abstract
Objective: To perform an analysis and review of the main articles available on the financial impact of meningomyelocele (MMC) and the cost-effectiveness of available treatments (fetal and neonatal surgery). Literature review: MMC generates a high cost related to the sequelae of malformations, with high consumption of health services and functional limitations of patients. The effect of the cost affects the health system (public or private) as a whole, as well as families, generating the concept of financial toxicity. Since the MOMS study was conducted in 2011, fetal surgery for the treatment of MMC has become widespread, with concern about the cost-effectiveness of the procedure. Considering the short- and medium-term results, several studies have considered that there are savings with the intrauterine procedure, even with the higher initial cost, which has the potential to reduce final healthcare expenses. Final considerations: MMC is a malformation of the CNS that has an impact on the development of cognitive and physical abilities of affected patients, with the possibility of fetal or neonatal treatment. Cost-effectiveness studies of fetal treatment are needed, compared to neonatal treatment, with data that show the Brazilian reality, where costs are different from those in high-income countries.
References
ACOG. Committee Opinion No. 720: Maternal–Fetal Surgery for Myelomeningocele. Obstet Gynecol, 2017; 130(3): e164–e167.
ADZICK NS, et al. A randomized trial of prenatal versus postnatal repair of myelomeningocele. N Engl J Med, 2011; 364(11): 993–1004.
AKSENOV LI, et al. Financial toxicity among individuals with spina bifida and their families: A qualitative study and conceptual model. JPediatrUrol, 2022; 18(3): 290.e1-290.e8.
BRASIL. REVISÃO DO ROL DE PROCEDIMENTOS E EVENTOS EM SAÚDE – 2018. RESUMO DA 3a REUNIÃO. Brasília. ANS Agência Nacional de Saúde Suplementar,2018. Disponível em: https://www.gov.br/ans/pt-br/arquivos/acesso-a-informacao/participacao-da-sociedade/camaras-e-grupos-tecnicos/camaras-e-grupos-tecnicos-anteriores/grupo-tecnico-do-cosaude-para-apreciacao-de-propostas-via-formulario-eletronico-para-as-alteracoes-no-rol-de-procedimentos-e-eventos-em-saude-2018/gt_cosaude_reuniao_3_ata.pdf. Acessado em: 12 de maio de 2022.
BRASIL. Sinasc - Tabnet. Disponível em:https://datasus.saude.gov.br/informacoes-de-saude-tabnet/. Acessado em: 8 de setembro de 2021.
BRASIL. PORTARIA No 53, 9 DE AGOSTO DE 2021. Disponível em: https://in.gov.br/en/web/dou/-/portaria-n-53-de-9-de-agosto-de-2021-337239208. Acessado em: 22 de julho de 2023.
BRASIL. O uso de limiares de custo-efetividade nas decisões em saúde: Recomendações da Comissão Nacional de Incorporação de Tecnologias no SUS. Brasília. Ministério da Saúde, 2022. Disponível em: https://www.gov.br/conitec/pt-br/midias/pdf/2022/20221106_relatorio-uso-de-limiares-de-custo-efetividade-nas-decisoes-em-saude.pdf. Acessado em: 7 de julho de 2023.
BRASIL. PARECER CONSELHO FEDERAL DE MEDICINA (CFM) no 2/2025 ASSUNTO: Atualização do Parecer CFM no 13/2018 – cirurgias fetais nas modalidades aberta e por fetoscopia indicadas para malformações congênitas. Disponível em: https://portal.cfm.org.br. Acessado em: 30 de janeiro de 2025.
CAHILL AG, et al. 397: Cost effectiveness of open fetal surgery for fetal myelomeningocele (MMC). Am J ObstetGynecol, 2012; 206(1): S185–S186.
CASSELL CH, et al. Health care expenditures among children with and those without spina bifida enrolled in Medicaid in North Carolina. Birth Defects Res A, 2011; 91(12): 1019–1027.
CIPE. InformeCIPE. Disponível em: https://cipe.org.br/novo/wp-content/uploads/2022/05/INFORME-CIPE-MIELOMENINGOCELE.pdf. Acessado em: 7 de março de 2025.
COLOMBO G, et al. A cost-of-illness study of spina bifida in Italy. ClinicoeconOutcomes Res, 2013; 5(1): 309-316.
DATASUS. Sigtap. Disponível em: http://sigtap.datasus.gov.br/tabela-unificada/app/sec/inicio.jsp. Acessado em: 7 de março de 2025.
DO T, et al. Healthcare Expenditures for the First Year of Life for United States Infants Born with Spina Bifida. J PediatrRehabil Med, 2017;10: S96.
FREITAS GL, et al. Vivência das famílias e o custo no cuidado de crianças e adolescentes com mielomeningocele. RevEnferm Cent.-Oeste Min, 2019; 9:e3282.
GROSSE S, et al. Lifetime costs of care for infants born with Spina Bifida in the United States. J PediatrRehabil Med, 2017;10:S62.
HOUTROWAJ, et al.Prenatal Repair and Physical Functioning Among Children with Myelomeningocele: A Secondary Analysis of a Randomized Clinical Trial. JAMAPediatr, 2021; 175(4):e205674.
INOUYE BM, et al. Hospital and ED charges for spina bifida care in the United States between 2006 and 2014: Over $2 billion annually. Disabil Health J, 2019; 12(3): 431–436.
KESSLER BA, et al. Cost of prenatal versus postnatal myelomeningocele closure for both mother and child at 1 year of life. Neurosurg Focus,2019; 47(4): E15.
KING BC, et al. Economic analysis of prenatal fetoscopic vs open‐hysterotomy repair of open neural tube defect. Ultrasound Obstet Gynecol, 2021; 58(2): 230–237.
LIPTAK GS, et al. Life course health and healthcare utilization among adults with spina bifida. Dev Med Child Neurol, 2016; 58(7): 714–720.
LOFTUS CJ, et al. MP47-06 Hospitalization Costs Are Increasing for Pediatric Patients with Spina Bifida: A National Analysis of 2006-2016. JUrol, 2021;206: e825.
MARQUART JP, et al. Controversies in Fetal Surgery. Clin Perinatol, 2022; 49(1): 267–277.
MOROZOWSKI AC. Impacto das decisões judiciais no orçamento da saúde: uma análise a partir de dados do Ministério da Saúde e da Secretaria de Saúde do Estado do Paraná. Revista de Direito Público da Economia RDPE, 2024; 22(86): 27–43.
PACEN,WILDEDJ. The Inspiring Tale of Infant Survival of Spina Bifida, a Historical Perspective. J PediatrRehabil Med, 2017; 10: S59.
PACKER CH, et al. Fetoscopic compared with open repair of myelomeningocele: a 2-delivery cost-effectiveness analysis. Am J Obstet Gynecol MFM, 2021; 3(6): 100434.
PEIXOTO-FILHO FM, et al. Historical Clinical Outcomes of Children with Myelomeningocele Meeting the Criteria for Fetal Surgery: A Retrospective Cohort Survey of Brazilian Patients. Rev Bras Ginecol Obstet, 2022; 44(3): 238–244.
PNEU J. Projeto De Lei N° 1701/2022. Disponível em: https://www.camara.leg.br/propostas-legislativas/2329471. Acessado em: 07 demarço de 2025.
RIDDLE S, et al. Morbidity and cost burden of prenatal myelomeningocele repair. J Matern Fetal Neonatal Med, 2021; 34(10): 1651–1657.
SACCO A, et al. A study to assess global availability of fetal surgery for myelomeningocele. PrenatDiagn, 2018; 38(13): 1020–1027.
SACCO A, et al. Fetal surgery for open spina bifida. Obstet Gynaecol, 2019; 21(4): 271–282.
SHAO B, et al. Prenatal Neurosurgical Counseling for Myelomeningocele and Treatment-Determining Factors for Fetal Repair. Fetal Diagn Ther, 2024: 1–9.
SHEPARD CL, et al. Ambulatory Care Use among Patients with Spina Bifida: Change in Care from Childhood to Adulthood. J Urol, 2018;199(4): 1050-1055.
TOWSE A, MAUSKOPF JA. Affordability of New Technologies: The Next Frontier. Value Health, 2018; 21(3): 249-251.
WADA S, et al. New challenges of fetal therapy in Japan. J Obstet Gynaecol Res, 2022; 48(8): 2100–2111.
WERNER EF, et al. Evaluating the cost-effectiveness of prenatal surgery for myelomeningocele: a decision analysis. Ultrasound Obstet Gynecol, 2012; 40(2): 158–164.
WORLEY G, et al. Neurosurgical procedures for children with myelomeningocele after fetal or postnatal surgery: a comparative effectiveness study. Dev Med Child Neurol, 2021; 63(11): 1294–1301.
YACOB A, et al. The Global Burden of Neural Tube Defects and Disparities in Neurosurgical Care. World Neurosurg, 2021; 149: e803–e820.
YI Y, et al. Economic burden of neural tube defects and impact of prevention with folic acid: a literature review. Eur J Pediatr, 2011; 170(11): 1391–1400.
ZANON N, et al. Spina bifida folate fortification in Brazil, update 2022: a cross-sectional study. Childs Nerv Syst, 2023; 39(7): 1765–1771.